These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

587 related items for PubMed ID: 16704648

  • 1. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris.
    Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, Fleming C, Heikkilä H, Jolliffe D, Peyri J, Svensson A, Toole J, Wozel G.
    Br J Dermatol; 2006 Jun; 154(6):1155-60. PubMed ID: 16704648
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris.
    Kragballe K, Noerrelund KL, Lui H, Ortonne JP, Wozel G, Uurasmaa T, Fleming C, Estebaranz JL, Hanssen LI, Persson LM.
    Br J Dermatol; 2004 Jun; 150(6):1167-73. PubMed ID: 15214905
    [Abstract] [Full Text] [Related]

  • 3. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris.
    Kragballe K, Austad J, Barnes L, Bibby A, de la Brassinne M, Cambazard F, Fleming C, Heikkilä H, Williams Z, Peyri Rey J, Svensson A, Toole J, Wozel G.
    Dermatology; 2006 Jun; 213(4):319-26. PubMed ID: 17135738
    [Abstract] [Full Text] [Related]

  • 4. The impact of a two-compound product containing calcipotriol and betamethasone dipropionate (Daivobet/ Dovobet) on the quality of life in patients with psoriasis vulgaris: a randomized controlled trial.
    van de Kerkhof PC.
    Br J Dermatol; 2004 Sep; 151(3):663-8. PubMed ID: 15377355
    [Abstract] [Full Text] [Related]

  • 5. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial.
    Saraceno R, Andreassi L, Ayala F, Bongiorno MR, Giannetti A, Lisi P, Martini P, Peris K, Peserico A, Chimenti S.
    J Dermatolog Treat; 2007 Sep; 18(6):361-5. PubMed ID: 17934937
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
    van de Kerkhof PC, Hoffmann V, Anstey A, Barnes L, Bolduc C, Reich K, Saari S, Segaert S, Vaillant L.
    Br J Dermatol; 2009 Jan; 160(1):170-6. PubMed ID: 19067709
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study.
    Buckley C, Hoffmann V, Shapiro J, Saari S, Cambazard F, Milsgaard M.
    Dermatology; 2008 Jan; 217(2):107-13. PubMed ID: 18463448
    [Abstract] [Full Text] [Related]

  • 16. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study.
    Fleming C, Ganslandt C, Guenther L, Johannesson A, Buckley C, Simon JC, Stegmann H, Vestergaard Tingleff L.
    Eur J Dermatol; 2010 Jan; 20(4):465-71. PubMed ID: 20413372
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and local safety of a calcipotriol/ betamethasone dipropionate ointment in elderly patients with psoriasis vulgaris.
    Parslew R, Traulsen J.
    Eur J Dermatol; 2005 Jan; 15(1):37-9. PubMed ID: 15701591
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of once-daily treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol in the treatment of Psoriasis vulgaris.
    Peeters P, Ortonne JP, Sitbon R, Guignard E.
    Dermatology; 2005 Jan; 211(2):139-45. PubMed ID: 16088161
    [Abstract] [Full Text] [Related]

  • 19. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting.
    van de Kerkhof PC, van der Valk PG, Swinkels OQ, Kucharekova M, de Rie MA, de Vries HJ, Damstra R, Oranje AP, de Waard-van der Spek FB, van Neer P, Lijnen RL, Kunkeler AC, van Hees C, Haertlein NG, Hol CW.
    Br J Dermatol; 2006 Oct; 155(4):800-7. PubMed ID: 16965431
    [Abstract] [Full Text] [Related]

  • 20. A two-compound product containing calcipotriol and betamethasone dipropionate provides rapid, effective treatment of psoriasis vulgaris regardless of baseline disease severity.
    van de Kerkhof PC, Wasel N, Kragballe K, Cambazard F, Murray S.
    Dermatology; 2005 Oct; 210(4):294-9. PubMed ID: 15942215
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.